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Abstract. RTS,S/AS01E malaria vaccine safety, effectiveness, and impact will be assessed in pre- and post-vaccine
introduction studies, comparing the occurrence of malaria cases and adverse events in vaccinated versus unvaccinated
children. Because those comparisons may be confounded by potential year-to-year fluctuations in malaria transmission
intensity and malaria control intervention usage, the latter should be carefully monitored to adequately adjust the analyses.
This observational cross-sectional study isassessingPlasmodium falciparumparasiteprevalence (PfPR) andmalariacontrol
intervention usage over nine annual surveys performed at peak parasite transmission. Plasmodium falciparum parasite
prevalence wasmeasured bymicroscopy and nucleic acid amplification test (quantitative PCR) in parallel in all participants,
and defined as the proportion of infected participants among participants tested. Results of surveys 1 (S1) and 2 (S2),
conducted in five sub-Saharan African countries, including some participating in the Malaria Vaccine Implementation Pro-
gramme (MVIP), are reported herein; 4,208 and 4,199 children were, respectively, included in the analyses. Plasmodium
falciparum parasite prevalence estimated using microscopy varied between study sites in both surveys, with the lowest
prevalence inSenegalese sites and the highest inBurkina Faso. In sites located in theMVIPareas (KintampoandKombewa),
PfPR inchildren aged6months to4 years ranged from24.8% to 27.3%, dependingon thestudy site and the survey.Overall,
89.5%and 86.4%of children used a bednet in S1 andS2, of whom68.7%and 77.9%used impregnated bednets. Nomajor
difference was observed between the two surveys in terms of PfPR or use of malaria control interventions.
INTRODUCTION
Substantial investment to expand existing malaria inter-
ventionshas resulted in a reduction in theglobal incidence rate
of malaria between 2010 and 2017.1 However, between 2015
and 2017, after stagnation, a slight upward trend in malaria
incidence was observed. Malaria remains a major cause of
death worldwide, with approximately 93% of all malaria
deaths in 2017 occurring in Africa.1 To reach the Global
Technical Strategy for Malaria 2016–2030 target of reducing
globalmalaria incidence andmortality rates by at least 90%by
2030,2 the need for safe and effective malaria vaccines that
prevent disease and death and decrease transmission to en-
ablemalaria eradicationwas endorsed anddocumented in the
WHO Malaria Vaccine Technology Roadmap.3
GlaxoSmithKline (GSK) has developed, in partnership with
the PATH Malaria Vaccine Initiative, a pre-erythrocytic Plas-
modium falciparum malaria vaccine, RTS,S/AS01E (GSK™,
Wavre, Belgium), for routine immunization of infants and
children living in sub-Saharan African (SSA) malaria-endemic
countries. In 2015, theEuropeanMedicinesAgency adopted a
positive opinion for the use of the vaccine in children aged
6 weeks to 17 months at the first dose.4 In January 2016, the
WHO recommended a pilot implementation of RTS,S/AS01E
in children as of 5 months of age in three to five epidemio-
logical SSA settings with moderate to high malaria trans-
mission.5 In April 2017, the WHO announced the vaccine
introduction based on a cluster-randomized design in pilot
areas of Ghana, Kenya, and Malawi through the national ex-
panded programs on immunization, in the framework of the
Malaria Vaccine Implementation Programme (MVIP).6 Today,
RTS,S/AS01E is the first vaccine implemented for the pre-
vention of malaria.
To assess vaccine safety, effectiveness, and impact, GSK
designed a pre- and a post-vaccine introduction observa-
tional study (Clinical Trials.gov identifiers: NCT02374450 and
NCT03855995, respectively), allowing comparison of the oc-
currence of malaria cases and adverse events in vaccinated
versus unvaccinated children. In parallel with those studies,
the present observational cross-sectional annual study
(NCT02251704) is estimating P. falciparum parasite preva-
lence (PfPR) and the use of malaria control interventions
during up to nine consecutive years, applying standardized
methodologies and multiple diagnostic testing. More specifi-
cally, considering the WHO recommendation to operate the
MVIP in moderate to high transmission areas of SSA, this
study will allow 1) characterizing the malaria transmission in-
tensity (MTI) before RTS,S/AS01E vaccine introduction in dif-
ferent countries/areas, including the ones participating in the
MVIP; 2) monitoring overtime fluctuations of MTI and of the
use of malaria control interventions before and after vaccine
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introduction in those areas to adjust the pre- andpost-vaccine
introduction comparison analyses for potential year-to-year
and/or geographical variations.
We present here the results of the first two annual surveys
that were conducted before vaccine introduction. On com-
pletion of all surveys, the data collected in this study involving
approximately 50,000 participants representing multiple sites
in various SSA countries will provide a unique perspective on
malaria prevalence variations across Africa.
MATERIALS AND METHODS
Ethics. The study was approved by national independent
Ethics Committees and local institutional review boards in
Burkina Faso (BF), Ghana (GH), Kenya (KE), Senegal (SN), and
Tanzania (TZ), and conducted in accordance with the provi-
sions of the International Conference on Harmonisation and
Good Clinical Practice guidelines.
Study population. Individuals aged 6months to < 10 years,
whose parents or legally acceptable representative had pro-
vided informedconsent for studyparticipation, were randomly
selected each year in each of the study sites (see Studydesign
section) using population listings generated from local Health
andDemographic SurveillanceSystems (HDSS) and following
a stratification by age-group (see the Supplemental Appendix
Section 1). Children in care, or actively participating in any trial
involving the administration of an investigational malaria
vaccine and/or drug, were excluded.
Study design. Malaria transmission intensity levels are
consensus indicators developed by the Global Malaria Eradi-
cation Programme to measure malaria endemicity7 using a
standardized methodology. There are several methods for es-
timating MTI, including entomological inoculation rates (EIRs),
serological conversion rates (SCRs), and blood parasite prev-
alence. Although EIR is a standard method, the measure is
challenging, and the interpretation and comparability of the
setting may be difficult because of vector heterogeneity.8 The
methodologyand interpretationofSCRs toclassify the intensity
of malaria is still not commonly used. Plasmodium falciparum
prevalence, despite requiring trained staff for slide reading,
provides a standardized and relatively easy to implement
method to assess MTI in study sites of varied transmission
intensity, and has often been used in previous epidemiological
studies.7,9,10 Therefore, PfPR was the selected method to as-
sess potential variations in MTI in the present study.
The study is multicentric with study sites corresponding
to geographically limited catchment areas located in low,
moderate, or high MTI regions of SSA, and having an HDSS
in place.
Up tonine annual cross-sectional surveyswill be conducted
during themalaria peak transmission period in each study site
(from mid-September to mid-December in Western African
sites and from mid-April to mid-August in Eastern African
sites). To optimize the detection of the peak transmission,
each study site has been equipped with a weather station to
record meteorological data such as rainfall, temperature, and
humidity. Surveys were conducted during the course of the
rainy season preferably when rains decrease, which should
correspond to the period of highest malaria transmission. In
this article, results of the first two annual surveys are pre-
sented. Survey 1 (S1) and survey 2 (S2) were conducted in
seven study sites in five SSA countries: BF (Nouna, Saponé),
GH (Kintampo), KE (Kombewa), SN (Keur Socé, Niakhar), and
TZ (Korogwe). Sites in GH (Kintampo) and KE (Kombewa) are
part of the areas where the RTS,S/AS01E vaccination will be
implemented through the national Expanded Programs on
Immunization in the framework of the MVIP. It is important to
note that this study is also conducted in SSA areas where the
RTS,S/AS01E vaccine will not be introduced in the framework
of the MVIP because GSK initiated the study before the WHO
recommendation.5,11
Data collection. Demographic details (age and gender),
medical history, and information on care-seeking behaviors
(hospitalization for malaria within the last 3 months, visits to
healthcare provider for fever or malaria treatment in the pre-
vious 14 days, anti-malaria therapy received within the last
14 days); malaria control intervention usage (bednets [new
{not older than a year}, pierced/torn, impregnated], indoor
residual spraying [IRS]); the usage of coils, repellents, and
local herbs; andmalaria potential risk factors (rural/urban area,
house construction materials, use of electricity, and open/
closed water source) were recorded for all participants at the
time of the survey. Axillary body temperature was measured
and recorded during the survey visit.
To assess within-site heterogeneity of PfPR, study areas
were mapped by villages using grid referencing and divided
into 3–14 segments with a minimum of 10 enrolled individuals
per segment. Segments will remain unchanged for the dura-
tion of the study.
Assessment of parasitemia. Both microscopy and Nucleic
Acid Amplification Tests (NAATs) were used in parallel on all
participants to assess parasitemia. The latter are expected to
be more sensitive and specific, particularly in cases of low
parasite density.12,13 In brief, a blood sample was collected
by finger prick for thin and thick blood films for the micros-
copy assessment and filter paper blood spots for NAATs.
Blood smears were examined by two local independent mi-
croscopists, and any discrepancies were settled by a third
reader. Parasitemiawasmeasured by the examination of 100
high-powered fields on thick smear to determine the pres-
ence of parasites; in the case of a positive result, additional
100 fields were examined to assess the presence of multiple
species. Plasmodium species and sexual forms were iden-
tified on thin blood film. Parasite density was computed as
the geometric mean of two readings, counting parasites
against 200 white blood cells on thin blood film, assuming
8,000white blood cells/μL. Parasite density was categorized
as low (< 2,500 parasites/μL), medium (2,500–9,999), high
(10,000–19,999), or very high (> 20,000). In the case of low
density (< 10 parasites against 200 leukocytes), parasite
count was conducted against 500 white blood cells. The
parasite count technique was replicated to count gameto-
cytes. In parallel with microscopy, asexual and sexual par-
asitemia was assessed by NAATs using both real-time
quantitative PCR (QT-PCR) assay and real-time nucleic acid
sequence-based amplification (QT-NASBA) assay. Quanti-
tative PCR allowed detection of asexual and sexual para-
sites combined, the final output being qualitative (positive
or negative) and semi-quantitative (high, medium, low, and
negative). QT-NASBA allowed detection of gametocytes,
the final output being qualitative (positive or negative). De-
tails for blood slide andNAATassessment of parasitemia are
available in the Supplemental Appendix (Sections 2 and 3,
respectively).
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If fever (i.e., axillary temperature ³ 37.5C) was recorded at
the time of the visit or reported to have occurred within 24
hours before the visit, a malaria rapid diagnostic test (RDT)
was conducted using blood from the finger prick sampling. If
the RDT was positive, then treatment was given according to
national guidelines. Moreover, any participant identified as
being parasite positive following microscopy was traced to
receive treatment according to national guidelines.
Statistical methods. The planned sample size was 600
participants per study site and per survey distributed as 400
participants between the ages of 6 months to 4 years and
200 participants between the ages of 5 and 9 years. The
sample size was calculated to ensure sufficiently narrow CIs
around study site–specific PfPR estimates (with a maximum
residual standard error of 0.25).
Plasmodium falciparumparasiteprevalenceandprevalence
of gametocytes were estimated as the proportion of partici-
pants infected, or carrying gametocytes, respectively, among
participants tested. Prevalences were estimated by age and
by site. The agreement between the two diagnostic methods
used in the framework of this study (parasitemia measured by
microscopy versus NAATs) was described using the Cohen’s
kappa coefficient and assessed using the Landis and Koch
scale.14 The prevalence of Plasmodium species other than
P. falciparum was estimated as the proportion of infected
participants among participants tested. The within-site het-
erogeneity between segmentswas tested using Cochran’sQ-
test based on inverse variance weights.
Malaria control intervention coverage was estimated as the
proportion of users among participants for which this in-
formation was available. The care-seeking behaviors (treat-
ment sought for malaria or fever in the 14 days before the visit
and hospitalization for malaria in the last 3 months before the
visit) were described as the proportion of participants having
sought for health care amongall participants. In addition, a risk
factor analysis for malaria infection (dependent variable:
P. falciparum parasitemia as measured by microscopy) was
conducted using amultivariable logistic regression with study
site as cluster and using a backward strategy for the selection
of significant explanatory variables, that is, predefined po-
tential risk factors and/or the use of malaria control interven-
tions (Supplemental Appendix Section 4). Age was computed
as a continuous variable.
RESULTS
Survey 1 andS2datawere collectedbetweenOctober 2014
and August 2015, and between September 2015 and July
2016, respectively. During S1 and S2, 4,215 and 4,204 chil-
dren were enrolled and 4,208 and 4,199 were included in the
analyses (Figure 1), with a balanced distribution across the
seven study sites (Supplemental Table 1). Across all sites,
51.3% of participants in S1 and 50.3% in S2 were males
(Supplemental Table 2).
Year-to-year variation in P. falciparum prevalence.
Plasmodium falciparum parasite prevalence estimated using
microscopy varied between study sites in both surveys, with
the lowest prevalence figures in Senegalese sites and the
highest in BF (Table 1, Figure 2). In Kintampo and Kombewa
sites that are located in the MVIP areas, PfPR in children aged
6 months to 4 years ranged from 24.8% to 27.3% depending
on the study site and the survey. In both surveys and across all
sites except in SN, PfPR was lower in the 6-month to < 5-year
than in the 5-year to < 10-year age-group. Plasmodium falci-
parum parasite prevalence was similar in S1 and S2, except
for a higher prevalence in S2 in participants from the 6-month
FIGURE 1. Study design overview and study population included in the analysis. ICF = inform consent form; N = number of participants in each
group; 6 M to < 5 Y = 6 months to younger than 5 years; 5 Y to < 10 Y = 5 years to younger than 10 years.
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to < 5-year age-group in BF Nouna and lower prevalence in
S2 in both the 6-month to < 5-year and 5-year to < 10-year
age-groups in participants from TZ Korogwe. Significant
within-site heterogeneity was detected in all sites, except in
SN: BF Nouna (S1 P < 0.0001, S2 P = 0.0184), BF Saponé (S1
P=0.0321, S2P<0.0001), TZKorogwe (S1P= 0.0037, S2P=
0.0275), KE Kombewa (S1P = 0.0220, S2P < 0.0001), andGH
Kintampo (S2 only P = 0.0065).
Similar trends were observed when measured by QT-PCR,
with PfPR varying from 2.7% in SN Niakhar to 69.9% in BF
Nouna (notmeasured in SNKeur Socé) in S1 and from1.3% in
SN Keur Socé to 76.3% in BF Nouna in S2 (Supplemental
Table 3).
The prevalence of gametocytes measured by microscopy
ranged from 0.5% to 4.0% in S1 and from 0.0% to 5.3% in S2
in all sites, except in BF (15.8% and 22.7% in S1 and 12.8%
and 18.2% in S2 in Nouna and Sapone, respectively). Among
participants tested positive for asexual parasites, 7.5–66.7%
carriedgametocytes inS1 (KintampoandKeurSocé, respectively)
and 0.0–83.3% in S2 (Niakhar and Keur Socé, respectively)
(Table 2). The proportion of infected participants carrying ga-
metocytesasestimatedbyQT-NASBAranged from13.3%inSN
Niakhar to 59.2% in BF Sapone in S1 (not measured in Keur
Socé) and from7.1% inSNNiakhar to 66.7% inSNKeur Socé in
S2 (Supplemental Table 3).
Agreement between diagnostic tests. Across surveys,
approximately 21.6% of participants with a positive QT-PCR
result had a negative microscopy reading (285 of 1,268 posi-
tive participants per QT-PCR in S1 and 296 of 1,417 in S2) and
around 8.8% of participants positive for microscopy had a
negative result with QT-PCR (92 of 1,075 positive participants
per microscopy in S1 and 110 of 1,231 in S2) (Table 3). The
proportion of participants with a negative result by micros-
copy among participants with a positive QT-PCR ranged
TABLE 1
Plasmodium falciparum parasitemia prevalence measured by microscopy by study site and survey according to age-group
P. falciparum parasitemia prevalence measured by microscopy slide reading
Age-group Study site
Survey 1 Survey 2
n N Proportion (%) 95% CI n N Proportion (%) 95% CI
6 M to < 5 Y Nouna, BF 249 404 61.6 56.7; 66.4 321 400 80.3 76.0; 84.0
Saponé, BF 162 403 40.2 35.4; 45.2 182 399 45.6 40.7; 50.6
Kintampo, GH 99 400 24.8 20.6; 29.3 109 400 27.3 22.9; 31.9
Kombewa, KE 100 402 24.9 20.7; 29.4 108 401 26.9 22.7; 31.6
Keur Socé, SN 2 400 0.5 0.1; 1.8 4 397 1.0 0.3; 2.6
Niakhar, SN 6 398 1.5 0.6; 3.3 1 397 0.3 0.01; 1.4
Korogwe, TZ 29 401 7.2 4.9; 10.2 6 400 1.5 0.6; 3.2
5 to < 10 Y Nouna, BF 154 202 76.2 69.8; 81.9 167 200 83.5 77.6; 88.4
Saponé, BF 137 201 68.2 61.2; 74.5 134 200 67.0 60.0; 73.5
Kintampo, GH 115 200 57.5 50.3; 64.4 103 200 51.5 44.4; 58.6
Kombewa, KE 96 197 48.7 41.6; 55.9 81 198 40.9 34.0; 48.1
Keur Socé, SN 1 200 0.5 0.01; 2.8 2 203 1.0 0.1; 3.5
Niakhar, SN 3 200 1.5 0.3; 4.3 2 204 1.0 0.1; 3.5
Korogwe, TZ 34 200 17.0 12.1; 22.9 12 200 6.0 3.1; 10.3
BF = Burkina Faso; GH = Ghana; KE = Kenya; SN = Senegal; TZ = Tanzania; n = number of participants positive for P. falciparum parasitemia measured by microscopy; N = number
of participants with known result for P. falciparummicroscopy; P. falciparum = Plasmodium falciparum; 6 M to < 5 Y = 6 months to younger than 5 years; 5 Y to < 10 Y = 5 years to younger than
10 years; 95% CI = exact 95% CI.
FIGURE 2. Plasmodium falciparum parasitemia prevalence measured by microscopy, by age category, and by site. 6 M to < 5 Y = 6 months to
younger than 5 years; 5 Y to < 10 Y = 5 years to younger than 10 years. Error bars depict 95% CI.
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between 42.9% and 78.6% in sites with low MTI (Niakhar,
Keur Socé, and Korogwe).
Across all sites, Cohen’s kappa coefficient between quali-
tative results of the two methods of measurement of para-
sitemia (microscopy versus QT-PCR) using the Landis and
Koch scale showed a substantial agreement in both surveys
(S1: kappa = 0.75 [95%CI: 0.73; 0.78]; S2: kappa = 0.78 [95%
CI: 0.75; 0.80]). Cohen’s kappa coefficient between semi-
quantitative results for parasitemia measured by microscopy
versus QT-PCR also showed a substantial agreement in both
S1 (kappa = 0.65 [95% CI: 0.63; 0.68]) and S2 (kappa = 0.66
[95% CI: 0.64; 0.68]).
Between 25.0% (192 of 767 in S2) and 33.8% (185 of 548
in S1) of participants tested positive for gametocytes by
QT-NASBA were also detected positive by microscopy
(Supplemental Table 4).
Prevalence of Plasmodium species other than
P. falciparum. Infection with Plasmodium malariae was ob-
served in 1.5% of participants in S1 and 3.0% of participants in
S2 (Supplemental Table 5). Coinfectionwith bothP.malariaeand
P. falciparum was more frequent than single infection with P.
malariae alone in both surveys (S1: 4.6%versus 0.2%; S2: 7.4%
versus 1.2%).Of the 62participants inS1 and128participants in
S2 infectedwithP.malariae, 55 (88.7%)and91 (71.1%)werealso
infected with P. falciparum, respectively. Infection with Plasmo-
dium ovale was low in both S1 and S2 (0.5% and 0.2% of par-
ticipants). Plasmodium vivaxwas not observed in S1 and in only
one participant in S2. Infections with species other than
P. falciparum were mostly observed in sites of medium-to-high
P. falciparum prevalence.
Year-to-year variation in the use of malaria control
interventions. Overall, 89.5% and 86.4% of children used a
bednet the night before the survey in S1 and S2, respectively
(Table4,Supplemental Table6). Thehighestuseofbednetswas
in KE Kombewa (97.5%) in S1 and TZ Korogwe (99.2%) in S2,
and the lowest in GH Kintampo (70.2%) in S1 and SN Niakhar
(69.6%) in S2 (Table 4). A decrease in usage between the two
surveys was observed in Kombewa, Keur Socé, and Niakhar,
whereas an increase was observed in Kintampo and Korogwe.
Overall, 70–80%of thebednetswere impregnated, 60–70%
were new, and approximately 25% were torn (Supplemental
Table 6). Details for the characterization of bednet usage (new,
impregnated, and pierced/torn) by study site are shown in
Figure 3.
Participant’s recall of IRS in the past 12 months was
recorded for a very low number of participants (across sur-
veys, 4.1% overall), mainly in SN (Supplemental Table 7).
Overall, usage of coils and repellents was limited, around
10% of the population in both surveys with variations per site
between 1% and 40% according to the survey (Supplemental
Table 7).
Year-to-year variation in reported fever andcare-seeking
behaviors. Fever in the last 24 hours was reported for ap-
proximately a quarter of the participants in both surveys,
with differences across study sites ranging from 3.6% in BF
Saponé to 63.8% in KE Kombewa in S1 and from 3.0% in SN
Keur Socé to 71.6% in KE Kombewa in S2 (Supplemental
Table 8). Across all sites, occurrence of fever was higher
in P. falciparum–infected versus non-infected participants
(35.6% versus 21.1% in S1 and 33.5% versus 22.5% in S2,
respectively). In both surveys, fever was more frequently
reported by participants with higher parasite densities
(Supplemental Table 9).
In S1, 15.7% of participants had sought treatment against
malaria or fever in the 14 days before the survey compared
with 12.8% inS2, ranging from0.0% to up to 33.3%depending
on the study site and on the survey (Table 5, Supplemental
Table 10). Plasmodium falciparum–infected children sought
treatment against malaria or fever more often than non-infected
children (20.1% versus 14.0% in S1 and 20.0% versus 9.8% in
S2, respectively).
The proportion of participants hospitalized for malaria was
2.6% in S1 and 2.8% in S2, with no marked difference be-
tween P. falciparum–infected and non-infected participants
2.8% versus 2.5% in S1 and 3.4% versus 2.6% in S2, re-
spectively; (Table 5, Supplemental Table 10).
Association between potential risk factors and P.
falciparum infection. An exploratory multivariable model
was used to assess the association between potential risk
factors or malaria control interventions and P. falciparum
infection. Across both surveys, houses equipped with elec-
tricity (odds ratio [OR]: S1 0.75 [95% CI: 0.61; 0.93]; S2 0.89
[95% CI: 0.80; 0.98]), cement/plaster walls versus mud (OR:
S1 0.81 [95% CI: 0.69; 0.96]; S2 0.87 [95% CI: 0.76; 0.99]),
and nets on all windows (OR: S1 0.73 [95%CI: 0.63; 0.84]; S2
0.79 [95%CI: 0.66; 0.94]) were associatedwith a lower risk of
infection with P. falciparum. In addition, older age was asso-
ciated with a higher risk of infection (OR: 1.14 [95% CI: 1.05;
1.24] in S1 and 1.09 [95% CI: 1.02; 1.16] in S2; Supplemental
Tables 11 and 12).
Figure 4 represents a plain language summary, which
elaborates on the epidemiologic study relevance that could be
shared with patients by healthcare professionals.
DISCUSSION
CharacterizingMTI in different SSA settings.UsingPfPR
as a proxy, this study aims at characterizing MTI15 in different
SSA settings, including areas in GH and KE where the RTS,S/
AS01E malaria vaccine is currently introduced in the frame-
work of the MVIP. More specifically, considering the WHO
TABLE 2
Gametocyte results measured by microscopy according to P. falci-
parum infection status per study site and survey
Study site, n (%)
Gametocytes measured by microscopy
Participants positive for
P. falciparum by microscopy
Participants tested for
P. falciparum by microscopy
Survey 1 Survey 2 Survey 1 Survey 2
Nouna, BF N = 403 N = 488 N = 606 N = 600
Positive 89 (22.1) 76 (15.6) 96 (15.8) 77 (12.8)
Saponé, BF N = 299 N = 316 N = 604 N = 599
Positive 111 (37.1) 84 (26.6) 137 (22.7) 109 (18.2)
Kintampo, GH N = 214 N = 212 N = 600 N = 600
Positive 16 (7.5) 23 (10.9) 18 (3.0) 32 (5.3)
Kombewa, KE N = 196 N = 189 N = 599 N = 599
Positive 19 (9.7) 8 (4.2) 24 (4.0) 9 (1.5)
Keur Socé, SN N = 3 N = 6 N = 600 N = 600
Positive 2 (66.7) 5 (83.3) 5 (0.8) 5 (0.8)
Niakhar, SN N = 9 N = 3 N = 598 N = 601
Positive 1 (11.1) 0.0 (0) 3 (0.5) 0.0 (0)
Korogwe, TZ N = 63 N = 18 N = 601 N = 600
Positive 7 (11.1) 1 (5.6) 8 (1.3) 1 (0.2)
BF = Burkina Faso; GH = Ghana; KE = Kenya; SN = Senegal; TZ = Tanzania; n (%) =
number (percentage) of participants in a given category; N = total number of participants;
P. falciparum = Plasmodium falciparum.
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recommendation to operate the MVIP in moderate to high
transmission areas of SSA, PfPR in children aged 6months to
4 years in Kintampo and Kombewa sites was high, ranging
from 24.8% to 27.3% depending on the study site and the
survey. Similar PfPR was estimated by Drakeley et al.,9 in-
dicating a stable mesoendemic MTI level (PfPR = 10–50%) in
those areas.10,16 Plasmodium falciparum parasite prevalence
varied largely between sites as it was expected from various
preselected transmission intensity areas. In both surveys, the
two sites in BF had the highest PfPR and the two sites in SN,
the lowest. Plasmodium falciparum parasite prevalence rates
recorded in this study are in line with previous findings.9,16–18
Across most sites, the PfPR was lower in the 6-month to
< 5-year than in the 5-year to < 10-year age-group. In addition,
a risk factor analysis highlighted an association between older
age and higher risk of infection. Those results corroborate the
findings of other studies, identifying increasing age as a risk
factor for carrying malaria blood stage parasites.9,16,19 This
may potentially be explained by the fact that younger children
benefit from a more focused usage of control interventions
(bednets).20 Another explanation would be increased immu-
nity in older children due to repeated exposure to the parasite,
TABLE 3





Survey 1 Survey 2
QT-PCR QT-PCR
Positive (N = 1,268) Negative (N = 2,069)
Total
N = 3,337
Positive (N = 1,417) Negative (N = 2,737)
Total
(N = 4,154)n % n % n % n %
Nouna, BF Positive n 347 90.1 38 9.9 385 400 82.1 87 17.9 487
% 85.5 – 21.7 – 87.5 – 61.3 –
Negative n 59 30.1 137 69.9 196 57 50.9 55 49.1 112
% 14.5 – 78.3 – 12.5 – 38.7 –
Total n 406 – 175 – 457 – 142 – –
Saponé, BF Positive n 212 99.1 2 0.9 214 312 98.7 4 1.3 316
% 86.2 – 1.1 – 80.0 – 1.9 –
Negative n 34 16.0 178 84.0 212 78 27.6 205 72.4 283
% 13.8 – 98.9 – 20.0 – 98.1 – –
Total n 246 – 180 – – 390 – 209 – –
Kintampo, GH Positive n 188 90.0 21 10 209 201 94.8 11 5.2 212
% 81.4 – 6.3 – 71.5 3.4 –
Negative n 43 12.1 313 87.9 356 80 20.6 308 79.4 388
% 18.6 – 93.7 – 28.5 96.6 –
Total n 231 – 334 – – 281 – 319 – –
Kombewa, KE Positive n 174 88.8 22 11.2 196 185 97.9 4 2.1 189
% 66.4 – 6.5 – 78.4 – 1.1 –
Negative n 88 21.8 315 78.2 403 51 12.4 359 87.6 410
% 33.6 – 93.5 – 21.6 98.9 –
Total n 262 – 337 – – 236 363 – –
Keur Socé, SN Positive n – – – – – 4 66.7 2 33.3 6
% – – – – 57.1 0.4 –
Negative n – – – – – 3 0.5 547 99.5 550
% – – – – 42.9 – 99.6 –
Total n – – – – 7 – 549 – –
Niakhar, SN Positive n 7 87.5 1 12.5 8 3 100.0 0 0.0 3
% 46.7 – 0.2 21.4 – 0.0 – –
Negative n 8 1.4 549 98.6 557 11 1.8 587 98.2 598
% 53.3 – 99.8 – 78.6 – 100.0 – –
Total n 15 – 550 – – 14 – 587 – –
Korogwe, TZ Positive n 55 87.3 8 12.7 63 16 88.9 2 11.1 18
% 50.9 – 1.6 – 50.0 – 0.4 – –
Negative n 53 9.9 485 90.1 538 16 2.7 566 97.3 582
% 49.1 – 98.4 – 50.0 – 99.6 – –
Total n 108 – 493 – – 32 – 568 – –
Overall total Positive n 983 91.4 92 8.6 1,075 1,121 91.1 110 8.9 1,231
% 77.5 4.4 – 79.1 4.0 –
Negative n 285 12.6 1,977 87.4 2,262 296 10.1 2,627 89.9 2,923
% 22.5 – 95.6 – 20.9 – 96.0 –
Total n 1,268 – 2,069 – – 1,417 – 2,737 – –
BF = Burkina Faso; GH = Ghana; KE = Kenya; SN = Senegal; TZ = Tanzania; n = number of participants in a given category; P. falciparum = Plasmodium falciparum; QT-PCR = quantitative
PCR; % = percentage of participants with available results.
TABLE 4
Bednet usage the night before the survey by study site and survey
Site, country
Bednet usage the night before the survey
Survey 1 (N = 4,208) Survey 2 (N = 4,199)
N % (95% CI) n % (95% CI)
Nouna, BF 547 90.3 (87.6; 92.5) 530 88.3 (85.5; 90.8)
Saponé, BF 557 92.2 (89.8; 94.2) 534 89.1 (86.4; 91.5)
Kintampo, GH 421 70.2 (66.3; 73.8) 497 82.8 (79.6; 85.8)
Kombewa, KE 584 97.5 (95.9; 98.6) 534 89.1 (86.4; 91.5)
Keur Socé, SN 568 94.7 (92.6; 96.3) 520 86.7 (83.7; 89.3)
Niakhar, SN 547 91.5 (88.9; 93.6) 418 69.6 (65.7; 73.2)
Korogwe, TZ 544 90.5 (87.9; 92.7) 595 99.2 (98.1; 99.7)
Overall 3,768 89.5 (88.6; 90.5) 3,628 86.4 (85.3; 87.4)
BF=Burkina Faso;GH=Ghana; KE =Kenya; SN=Senegal; TZ = Tanzania; n (%) = number
(percentage) of children using a bednet the night before the visit in each site;N = total number
of participants; 95% CI = exact 95% CI.
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leading to asymptomatic carriage anda lower probability to be
treated than in symptomatic children.21,22
Infection with P. malariae was observed in a few partici-
pants, and infection with P. ovale was rare, which supports
observations from other studies conducted across SSA.23–26
Across all sites and surveys, only one Plasmodium vivax infection
was identified by microscopy in TZ, which differs from Twohig
etal.’s27 recentfindingsofgrowingevidenceof this species inSSA.
A high proportion of coinfections with P. falciparumwas observed
in P. malariae–infected participants (between 70% and 90%)
and P. ovale–infected participants (around 60%). Similarly, high
percentages ofP. falciparum coinfection inP.malariae–infected
participantswaspreviously reported inGuinea (97%),23Uganda
(91%),24 and in theDemocraticRepublic of theCongo (90%),25with
lower percentages reported in rural BF (67%)26 and Benin (34%).23
Approximately 20% of participants positive for P. falciparum
by QT-PCR were undetected by microscopy. Classifying the
study sites by MTI, this proportion was higher in low MTI sites.
This might be explained by a relatively lower sensitivity of
microscopy readings than nucleic acid related techniques,
particularly in low parasite density infections, which are more
frequently observed in low MTI areas.12,13 Nevertheless, the
kappa statistic estimated a substantial agreement between
microscopy and NAAT techniques using either qualitative or
semi-quantitative real-time PCR.
Monitoring year-to-year variations in MTI and in the use
of malaria control interventions. In addition, the present
results are establishing a standardized baseline for further
estimation of the year-to-year variations inPfPRand in the use
of malaria control interventions, which are key variables to be
monitored before and after vaccine introduction in the MVIP
areas. Little variation in P. falciparum prevalence between the
first two annual surveys was observed among most sites.
Usage of bednets as amalaria control intervention was high in
all sites and in both surveys (ranging 70–99%). Some variation
in the usage of bednetswas observed in all sites, except in BF.
In S2, participants not using mosquito coils, insecticide
sprays, or repellents against malaria vectors were significantly
less likely to be infectedwithP. falciparum (OR: S2 0.88 [95%CI:
0.782; 0.988]); however, no such association was observed in
S1. Various entomological studies have questioned the efficacy
of repellents and coils as effective malaria prevention measures
and highlighted the false sense of protection perceived by the
user.28–30 Our data do not allow to draw robust conclusions at
this stage, and the trend observed in S2 should be closely
monitored in the subsequent cross-sectional surveys.
Study limitations. As with all interview–questionnaire-
based studies, this study could have been subject to infor-
mation or recall bias as data related to bednet usage, control
interventions usage, and care-seeking behaviors were col-
lected from parents’ recollection as opposed to objective
observation. The impact of these potential information biases
on the study results is estimated to be limited because of the
proximity in time between the occurrence of the event for
FIGURE 3. Bednetcharacterization according toobsolescence, impregnation, andcondition, by surveyandbysite. impregnatedbednet=bednet
dipped in an insecticide liquid before or after purchase; new bednet = bednet not older than 1 year; S1 = survey 1; S2 = survey 2. Error bars depict
95% CI.
TABLE 5
Care-seeking behaviors (treatment sought for fever and hospitalization for malaria) according to P. falciparum infection status by microscopy and
survey
Care-seeking behavior Survey
P. falciparum infected P. falciparum not infected Total
N N % (95% CI) n N % (95% CI) n N % (95% CI)
Treatment sought for malaria or
fever in the previous 14 days
S1 238 1,187 20.1 (17.8; 22.4) 424 3,021 14.0 (12.8; 15.3) 662 4,208 15.7 (14.6; 16.9)
S2 247 1,232 20.0 (17.8; 22.4) 290 2,967 9.8 (8.7; 10.9) 537 4,199 12.8 (11.8; 13.8)
Hospitalization for malaria in the
past 3 months
S1 33 1,187 2.8 (1.9; 3.9) 76 3,021 2.5 (2.0; 3.1) 109 4,208 2.6 (2.1; 3.1)
S2 42 1,232 3.4 (2.5; 4.6) 77 2,967 2.6 (2.1; 3.2) 119 4,199 2.8 (2.4; 3.4)
n (%) = number (percentage) of children in each group; N = total number of participants; P. falciparum = Plasmodium falciparum; S1 = survey 1; S2 = survey 2; 95% CI = exact 95% CI.
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which information is collected and the interview itself. Another
study limitation may be related to both sensitivity and speci-
ficity of microscopy slide readings. Slide reading perfor-
mances may indeed vary depending on the parasite density
and species identification. However, the kappa statistic esti-
mated a substantial agreement betweenmicroscopy and QT-
PCR, the latter being able to detect a higher number of low
density infections than microscopy and RDT.12,31 Moreover,
this shouldmainly impact low transmission settings due to the
high proportion of low-density infections.
CONCLUSION
The present article summarizes the results of the first two
annual surveys of a larger malaria prevalence study aiming at
characterizing MTI in light of the use of malaria control inter-
ventions and other environmental factors. Our results confirm
that the high PfPR observed in study sites that are part of the
MVIP is in line with the WHO recommendation to operate the
program in moderate to high transmission areas. In addition,
our results are key to inform on the potential occurrence of
annual fluctuations in MTI that may influence the assessment
of the RTS,S/AS01E vaccine safety, effectiveness, and im-
pact. The observations based on the first two surveys of this
study do not indicate major temporal changes in terms of
Plasmodium prevalence or use of malaria control interven-
tions, but more surveys are needed to confirm this trend. The
data generated in this study will be used to create variables to
adjust the temporal and concurrent comparison analyses of
the RTS,S/AS01E vaccine safety, impact, and effectiveness
study. More specifically, the year- and site-specific PfPR
computed onunvaccinated studyparticipantswill be included
as covariates in the regression models of the safety, impact,
and effectiveness study to assess annual fluctuations and/or
changes due to other malaria control interventions.
To a broader extent, the large sample size of this study (ap-
proximately 50,000 participants during the course of 9 years) and
the use of a standardized methodology across multiple sites in
various countries in SSA using multiple testing will provide a
uniqueperspectiveonmalariaprevalencevariationsacrossAfrica.
ReceivedOctober 25, 2019. Accepted for publication August 7, 2020.
Published online September 21, 2020.
Note: Supplemental Appendix and tables appear at www.ajtmh.org.
Acknowledgments: We thank the children, their families, and their
communities who participated in this study; the investigators, and
their clinical and laboratory teams for their contribution to the study
and their support and care of participants; and also thank Shyam
Prasad TR (TCS c/o GSK) for data management, Aparna Yarraguntla
for statistical analysis (ICON, c/o GSK), Roland Vaudry (GSK) and
William Zonta (Modis, Belgium c/o GSK) for publicationmanagement,
and Sarah Benns (Independent medical writer on behalf of GSK) for
drafting the manuscript.
Financial support: This trial was sponsored and funded by
GlaxoSmithKline Biologicals SA (GSK). GSK also funded all costs
associated with the development and the publishing of the present
manuscript.
Disclosure: F. R., J.-Y. P., and S. W. are employees of the GSK group
of companies. At the time of the study, N. P. was an employee of the
FIGURE 4. Plain language summary. This figure appears in color at www.ajtmh.org.
1890 RTS,S EPIDEMIOLOGY EPI-MAL-005 STUDY GROUP
GSK group of companies. F. R., J.-Y. P., and N. P. hold shares in the
GSK group of companies. A. M., A. S., A. B. T., B. C., E. A., G. C., J. L.,
J. O., K. P. A., K. S., L. O., M. T., O. B., P. M., R. T., S. K., S. O.-A., S. B.
S., V. S.,W.O., andY.K., via their institutions, receivedgrants from the
GSK group of companies for the conduct of this study/work. A. S., A.
B. T., B. C., E. A., G. C., J. O., K. P. A., L. O., M. T., O. B., S. K., S. O.-A.,
S. B. S., V. S., W. O., and Y. K., via their institutions, received grants
from the GSK group of companies for the conduct of studies out-
side the submitted work. L. O. report grants from GSK Trust in
Science outside the submitted work. M. L. is an employee of Aixial
on behalf of the GSK group of companies. M. O. is an employee
of 4Clinics on behalf of the GSK group of companies. At the time of
the study, E. U. was a consultant for the GSK group of companies.
GSK makes available anonymized individual participant data and
associated documents from interventional clinical studies which
evaluate medicines, upon approval of proposals, submitted to
www.clinicalstudydatarequest.com. To access data for other types
of GSK sponsored research, for study documents without patient-
level data, and for clinical studies not listed, please submit an en-
quiry via the website. All authors reviewed and commented on a
draft version of the manuscript and gave their final approval for it to
be submitted for publication.
Authors’ addresses: Elisha Adeniji, Kwaku Poku Asante, Owusu
Boahen, Seyram Kaali, Seth Owusu-Agyei, and Mathilda Tivura, Kin-
tampoHealth Research Centre, Ghana Health Service, Accra, Ghana,
E-mails: elisha.adeniji@kintampo-hrc.org, kwakupoku.asante@kintampo-
hrc.org, owusu.boahen@kintampo-hrc.org, kaali.seyram@kintampo-hrc.
org, sowusuagyei@uhas.edu.gh, and mathilda.tivura@kintampo-
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Anta Diop, Dakar, Senegal, E-mails: khasylla@gmail.com and
rogertine@hotmail.com. Effua Usuf, Medical Research Council Unit,
The Gambia at London School of Hygiene and Tropical Medicine,
Fajara, The Gambia, E-mail: effuau@gmail.com.
This is an open-access article distributed under the terms of the
Creative Commons Attribution (CC-BY) License, which permits un-
restricted use, distribution, and reproduction in anymedium, provided
the original author and source are credited.
REFERENCES
1. World Health Organization, 2018. World Malaria Report 2018.
Available at: https://www.who.int/malaria/publications/
world-malaria-report-2018/report/en/. Accessed March 28,
2019.
2. World Health Organization, 2015. Global Technical Strategy for
Malaria 2016–2030. London, United Kingdom: WHO.
3. World Health Organization, Malaria Vaccine Funders Group,




4. European Medicines Agency SMH, 2015. First Malaria Vaccine
Receives Positive Scientific Opinion from EMA 2015. Available
at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/
news_and_events/news/2015/07/news_detail_002376.jsp&mid=
WC0b01ac058004d5c1. Accessed March 15, 2018.
5. World Health Organization, 2018. Malaria vaccine, 2016. WHO
position paper–January 2016.Wkly Epidemiol Rec 91: 33–52.
6. World Health Organization, 2017. Ghana, Kenya and Malawi to




7. Hay SI, Smith DL, SnowRW, 2008.Measuringmalaria endemicity
from intense to interrupted transmission. Lancet Infect Dis 8:
369–378.
8. Hay SI, Rogers DJ, Toomer JF, Snow RW, 2000. Annual Plas-
modium falciparum entomological inoculation rates (EIR)
across Africa: literature survey, internet access and review.
Trans R Soc Trop Med Hyg 94: 113–127.
9. Drakeley C et al., 2017. Longitudinal estimation of Plasmodium
falciparum prevalence in relation to malaria prevention mea-
sures in six sub-Saharan African countries.Malar J 16: 433.
10. Smith DL, Guerra CA, Snow RW, Hay SI, 2007. Standardizing
estimates of the Plasmodium falciparum parasite rate. Malar J
6: 131.
11. World Health Organization, 2017. Malaria Vaccine Implementation
Programme (MVIP). Available at: https://www.who.int/immunization/
diseases/malaria/malaria_vaccine_implementation_programme/
about/en/. AccessedMarch 22, 2019.
12. World Health Organization, 2019. Malaria: Areas of Work – Di-
agnostic Testing. Available at: https://www.who.int/malaria/
areas/diagnosis/nucleic-acid-amplification-tests/en/. Accessed
February 18, 2019.
13. Okell LC,Ghani AC, Lyons E, DrakeleyCJ, 2009. Submicroscopic
infection in Plasmodium falciparum-endemic populations:
a systematic review and meta-analysis. J Infect Dis 200:
1509–1517.
14. Landis JR, Koch GG, 1977. The measurement of observer
agreement for categorical data. Biometrics 33: 159–174.
15. The malERA Refresh Consultative Panel on Combination Inter-
ventions and Modelling, 2017. malERA: an updated research
agenda for combination interventions and modelling in malaria
elimination and eradication. PLoS Med 14: e1002453.
16. Diallo A et al., 2017. An epidemiological study to assess Plas-
modium falciparum parasite prevalence and malaria control
measures in Burkina Faso and Senegal.Malar J 16: 63.
17. Sylla K et al., 2015. Sero-epidemiological evaluation of Plasmo-
dium falciparummalaria in Senegal. Malar J 14: 275.
18. Tine RCK et al., 2013. Parasitic infections among children under
five years in Senegal: prevalence and effect on anaemia and
nutritional status. ISRN Parasitol 2013: 272701.
19. Ceesay SJ et al., 2008. Changes in malaria indices between 1999
and 2007 in The Gambia: a retrospective analysis. Lancet 372:
1545–1554.
20. Nankabirwa J, Brooker SJ, Clarke SE, Fernando D, Gitonga CW,
Schellenberg D, Greenwood B, 2014. Malaria in school-age
children in Africa: an increasingly important challenge. Trop
Med Int Health 19: 1294–1309.
21. Felger I, Maire M, Bretscher MT, Falk N, Tiaden A, SamaW, Beck
H-P, Owusu-Agyei S, Smith TA, 2012. The dynamics of natural
Plasmodium falciparum infections. PLoS One 7: e45542.
22. Aron JL, 1983. Dynamics of acquired immunity boosted by ex-
posure to infection.Math Biosci 64: 249–259.
23. CeesaySJet al., 2015.Malariaprevalenceamongyoung infants in
different transmission settings, Africa. Emerg Infect Dis 21:
1114–1121.
24. Asua V, Tukwasibwe S, Conrad M, Walakira A, Nankabirwa JI,
Mugenyi L, Kamya MR, Nsobya SL, Rosenthal PJ, 2017.
Plasmodium species infecting children presenting with malaria
in Uganda. Am J Trop Med Hyg 97: 753–757.
MTI AND CONTROL INTERVENTION STUDY 1891
25. Doctor SM et al., 2016. Low prevalence of Plasmodium malariae
and Plasmodium ovale mono-infections among children in the
Democratic Republic of theCongo: a population-based, cross-
sectional study.Malar J 15: 350.
26. Gneme A, GuelbeogoWM, Riehle MM, Tiono AB, Diarra A, Kabre
GB, Sagnon N, Vernick KD, 2013. Plasmodium species oc-
currence, temporal distribution and interaction in a child-aged
population in rural Burkina Faso.Malar J 12: 67.
27. Twohig KA, Pfeffer DA, Baird JK, Price RN, Zimmerman PA, Hay
SI, Gething PW, Battle KE, Howes RE, 2019. Growing evidence
ofPlasmodiumvivaxacrossmalaria-endemicAfrica.PLoSNegl
Trop Dis 13: e0007140.
28. Avicor SW, Wajidi MFF, Owusu EO, 2017. To coil or not to coil:
applicationpractices, perception andefficacyofmosquito coils
in a malaria-endemic community in Ghana. Environ Sci Pollut
Res Int 24: 21138–21145.
29. Hogarh JN,AgyekumTP,BempahCK,Owusu-AnsahEDJ,Avicor
SW, Awandare GA, Fobil JN, Obiri-Danso K, 2018. Environ-
mental health risks and benefits of the use of mosquito coils as
malaria prevention and control strategy.Malar J 17: 265.
30. Lukwa N, Chiwade T, 2008. Lack of insecticidal effect of mos-
quito coils containing either metofluthrin or esbiothrin on
Anopheles gambiae sensu lato mosquitoes. Trop Biomed 25:
191–195.
31. World Health Organization, 2017. Malaria Policy Advisory Com-
mittee (MPAC) Meeting Report 2017. Geneva, Switzerland:
WHO. Contract No.: WHO/HTM/GMP/MPAC/2017.21.
1892 RTS,S EPIDEMIOLOGY EPI-MAL-005 STUDY GROUP
